

## Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer

Jennifer Chae-Kim, Gunjal Garg, Larisa Gavrilova-Jordan, Lindsay Blake, Tongil "TI" Kim, Qiang Wu, Clifford Hayslip



### Highlights

- Women who receive progestin and metformin therapy have lower disease relapse than those receiving progestin alone.
- Combined therapy was not associated with significantly different disease remission, pregnancy or live birth rates.



### Study Design & Data

Systematic review and meta-analysis

6 studies  
(2 randomized, 4 retrospective)

Reproductive-aged women with atypical endometrial hyperplasia or early endometrial cancer, desiring fertility-sparing therapy




Three countries (USA, China, Japan), seven institutions

### Comparison




621 women


- 380 received progestin therapy
- 241 received combined therapy



Progestin (oral or intrauterine device)



Progestin with metformin



### Odds ratios of outcomes for combined therapy relative to progestin therapy

